絞り込み

16287

広告

Tumor Absorbed Dose for non-Hodgkin's Lymphoma Patients treated with the novel anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan.

著者 Blakkisrud J , Løndalen A , Martinsen AC , Dahle J , Holtedahl JE , Bach-Gansmo T , Holte H , Kolstad A , Stokke C
J Nucl Med.2016 Aug 4 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (19view , 0users)
  • このエントリーをはてなブックマークに追加

Full Text Sources

Miscellaneous

(177)Lu-lilotomab satetraxetan is a novel antibody radionuclide conjugate (ARC) currently tested in a phase 1/2a first-in-human dosage escalation trial for patients with relapsed CD37+ indolent non-Hodgkin's lymphoma. The aim of this work was to develop dosimetric methods and calculate tumor absorbed radiation doses for patients treated with (177)Lu-lilotomab satetraxetan.
PMID: 27493270 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード